Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Lately, Pfizer (NYSE: PFE) ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...